Cue Biopharma’s CUE-221 Clears Chronic Hives in Phase 2 Trial, Showing Lasting Benefit vs Xolair

Cue Biopharma’s CUE-221 met its Phase 2 goals in chronic hives, beating placebo and showing longer-lasting relief than Xolair after dosing stopped.